p-Iodphenyldiphenylmethylchlorid | 119291-43-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 三苯基化合物
• 英文名称: p-Iodphenyldiphenylmethylchlorid
• 英文别名: 4-iodo-trityl chloride；4-Jod-tritylchlorid；(4-Iodophenyl)diphenylmethyl chloride；1-[chloro(diphenyl)methyl]-4-iodobenzene
• CAS: 119291-43-9
• 化学式: C₁₉H₁₄ClI
• 分子量: 404.678
• InChiKey: WNMZPNMIKJLRKT-UHFFFAOYSA-N

物化性质

• 熔点：
  125 °C
• 沸点：
  444.8±33.0 °C(Predicted)
• 密度：
  1.519±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  6.1
• 重原子数：
  21
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.05
• 拓扑面积：
  0
• 氢给体数：
  0
• 氢受体数：
  0

反应信息

• 作为反应物：
  描述：

  p-Iodphenyldiphenylmethylchlorid 在 银 、 苯 作用下， 生成 1,2-bis-(4-iodo-phenyl)-1,1,2,2-tetraphenyl-ethane
  参考文献：
  名称：

  Organizational Buying and Advertising Agency-Client Relationships in China

  摘要：

  The 1980s and 1990s have seen the development of an interesting, diverse, and relevant body of literature on the advertising agency-client relationship. In recent times, an area of focus has been the application of organizational buying behavior principles to companies that are purchasing advertising services from advertising agencies. However, little is known about the application of such theories in the context of a developing country. After examining the literature relating to China's advertising industry and the application of organizational buying behavior principles in the advertising industry, this article reports on a survey of 200 firms in Shanghai. The results unexpectedly show that advertising agency power in the campaign development process is not related to the nature of the advertising task (new task, modified rebuy, straight rebuy) at hand. In addition, bottom-up processes give agencies the weakest pourer, and the client buying process is dominated by marketers, the salesforce, and public relations, with top managers the primary deciders.

  DOI：

  10.1080/00913367.2001.10673638
• 作为产物：
  描述：

  4-碘苯甲酸甲酯 、 phenylmagnesium bromide 生成 p-Iodphenyldiphenylmethylchlorid
  参考文献：
  名称：

  Tschitschibabin, Chemische Berichte, 1911, vol. 44, p. 442

  摘要：

  DOI：

文献信息

• BETA LACTAMS AS ANTIPROLIFERATIVE AGENTS
  申请人：——

  公开号：US20020082250A1

  公开（公告）日：2002-06-27

  This invention relates to a method of treating or reducing cell proliferation in a mammal in need thereof which comprises administering to said mammal an effective CoA-independent transacylase (CoA-IT) inhibiting amount of a compound of formula (I), wherein the variables of Y, X, m, R 3, R 4, R 10, R 20, R 5, R 6 and R 7 are defined in the specification. FIG. 3 demonstrates the ability of SB216754, ((3S,4R)-4-(isobutenyloxy)-3-triphenylmethylamino)azetidin-2-one) to decrease the viability of HL-60 cells.

  这项发明涉及一种治疗或减少哺乳动物细胞增殖的方法，包括向该哺乳动物施用化合物（I）的有效CoA独立转酰基酶（CoA-IT）抑制量，其中化合物的Y、X、m、R 3、R 4、R 10、R 20、R 5、R 6和R 7的变量在说明书中定义。图3展示了SB216754（（3S,4R)-4-(异丁烯氧基)-3-三苯甲基氨基)吖唑啉-2-酮）降低HL-60细胞存活能力的能力。
• Beta-lactam inhibitors of CoA-IT
  申请人：SmithKline Beecham Corporation

  公开号：US06221860B1

  公开（公告）日：2001-04-24

  This invention relates to methods for treating diseases or disorders mediated by lipid inflammatory mediators, arachidonic acid, its metabolites and/or platelet activating factor (PAF), which method comprises administration to a mammal in need thereof of an effective Coenzyme A independent transacylase (CoA-IT) inhibiting amount of a triphenylmethylazetidinone. This invention also relates to a method of treating or reducing inflammation in a mammal in need thereof, which comprises administering to said mammal an effective amount of a triphenylmethylazetidinone.

  本发明涉及用于治疗由脂质炎症介质、花生四烯酸、其代谢产物和/或血小板活化因子（PAF）介导的疾病或疾病的方法，该方法包括向需要该方法的哺乳动物施用有效的辅酶A独立转酰基酶（CoA-IT）抑制剂量的三苯甲基氮杂环己酮。本发明还涉及一种用于治疗或减轻需要该方法的哺乳动物中的炎症的方法，该方法包括向该哺乳动物施用有效量的三苯甲基氮杂环己酮。
• Gomberg; Cone, Chemische Berichte, 1906, vol. 39, p. 3278
  作者：Gomberg、Cone

  DOI：——

  日期：——
• Gomberg, Chemische Berichte, 1904, vol. 37, p. 1635
  作者：Gomberg

  DOI：——

  日期：——
• Gomberg, Chemische Berichte, 1907, vol. 40, p. 1886
  作者：Gomberg

  DOI：——

  日期：——